Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Growth and Strengthen Biologics CDMO Capabilities
Rezon Bio, a science-driven European contract development and manufacturing organization (CDMO) specializing in biologics, has announced the appointment of Dr. Hubert Scholze as its new Chief Business Officer (CBO), effective July 1, 2026. The appointment marks an important milestone for the company as it continues to expand its global commercial presence, enhance its integrated biologics development and manufacturing capabilities, and strengthen strategic partnerships with biotechnology and pharmaceutical companies worldwide.
As the demand for biologic medicines, biosimilars, and advanced therapeutic products continues to grow, CDMOs are playing an increasingly critical role in helping innovators accelerate drug development while navigating complex manufacturing and regulatory requirements. Rezon Bio’s decision to appoint an experienced commercial and manufacturing executive reflects its ambition to further position itself as a trusted global partner supporting clients from early-stage development through commercial production.
Strengthening the Executive Leadership Team
Dr. Scholze joins Rezon Bio as a member of the company’s Executive Leadership Team, where he will oversee all commercial operations and help shape the organization’s long-term business strategy.
In his new role, he will be responsible for leading several key business functions, including:
- Business Development
- Market Intelligence
- Global Marketing
- Proposal Management
- Project Management
By bringing these areas together under unified leadership, Rezon Bio aims to deliver an even more integrated experience for clients while aligning commercial strategy more closely with scientific expertise and manufacturing execution.
Beyond managing commercial operations, Dr. Scholze will be responsible for developing strategic partnerships, expanding international business opportunities, and ensuring that customers receive seamless support throughout every phase of their development programs—from the initial project discussion through manufacturing and delivery.
Supporting the Company’s Next Phase of Growth
The appointment comes during an important period of expansion for Rezon Bio.
The company has been investing in strengthening its integrated biologics CDMO platform to better serve developers of both innovative biologic medicines and biosimilar products. As biotechnology pipelines continue to expand globally, pharmaceutical companies increasingly seek development and manufacturing partners capable of providing comprehensive services across multiple stages of product development.
Rezon Bio is positioning itself to meet this demand by broadening its scientific capabilities, investing in manufacturing infrastructure, and expanding its international commercial reach.
Dr. Scholze’s appointment is intended to help accelerate these initiatives while ensuring that the company’s commercial organization continues to evolve alongside its growing technical capabilities.
Extensive Experience Across Manufacturing and Commercial Operations
Dr. Scholze brings more than 25 years of experience spanning biologics manufacturing, operational leadership, business development, and commercial strategy within both pharmaceutical companies and contract development and manufacturing organizations.
His career has provided experience across virtually every stage of biologics development, giving him a comprehensive understanding of both client needs and the operational challenges involved in bringing complex biologic therapies to market.
Before joining Rezon Bio, he served as the leader of Global Business Development for Catalent’s Core Biologics division.
In that position, he directed worldwide commercial activities supporting integrated mammalian drug substance development and sterile drug product manufacturing. His responsibilities included working closely with biotechnology companies and pharmaceutical organizations seeking end-to-end development and manufacturing solutions for biologic products.
The experience gained at one of the industry’s leading CDMOs provides him with valuable insight into global client expectations, evolving market trends, and increasingly sophisticated biologics manufacturing requirements.
A Career Built on Manufacturing Excellence
Unlike many commercial executives who begin their careers in sales or marketing, Dr. Scholze developed his expertise through hands-on manufacturing leadership.
He started his professional career at Boehringer Ingelheim in Vienna, where he held several leadership positions within biologics manufacturing.
Among his responsibilities were serving as:
- Unit Head of a large-scale microbial fermentation facility
- Manufacturing Director
These operational roles provided firsthand experience managing complex biologics production processes, overseeing manufacturing teams, and maintaining the quality standards required for pharmaceutical production.
His technical background allows him to understand manufacturing challenges from an operational perspective while effectively communicating with both scientific teams and commercial partners.
Transition into Global Business Development
After several years leading manufacturing operations, Dr. Scholze transitioned into commercial leadership, where he assumed positions of increasing responsibility across the pharmaceutical services industry.
During this phase of his career, he worked with several internationally recognized organizations, including:
- Boehringer Ingelheim
- Aenova Group
- Catalent
Across these organizations, he developed expertise in strategic business development, customer relationship management, and commercial planning while helping biotechnology companies advance therapeutic programs from early clinical development through large-scale commercial manufacturing.
His work has included collaborations with both emerging biotechnology startups and multinational pharmaceutical companies, giving him experience supporting a wide range of development strategies and organizational needs.
Supporting Biologics and Biosimilar Development
Rezon Bio has identified biologics and biosimilars as major strategic growth areas, reflecting broader trends across the global pharmaceutical industry.
Biologic medicines continue to represent one of the fastest-growing segments of healthcare, while biosimilars are expanding access to important therapies by providing lower-cost alternatives following patent expiration.
Developing and manufacturing these products requires highly specialized expertise, advanced process development capabilities, and sophisticated quality systems.
With extensive experience supporting integrated biologics programs, Dr. Scholze is expected to help strengthen Rezon Bio’s ability to meet these evolving industry demands while expanding partnerships with companies developing next-generation biologic therapies.
CEO Highlights Strategic Leadership
Commenting on the appointment, Dr. Adriana Kiędzierska-Mencfeld, Chief Executive Officer of Rezon Bio, emphasized that Dr. Scholze’s unique combination of technical and commercial expertise makes him an ideal addition to the executive leadership team.
She noted that his background spans manufacturing operations, commercial leadership, and deep knowledge of the biologics sector, providing valuable insight into the needs of both clients and development programs.
According to Dr. Kiędzierska-Mencfeld, his leadership will help further integrate Rezon Bio’s commercial strategy with its scientific excellence and operational execution, ultimately delivering greater value for customers as the company enters its next stage of international growth.
A Shared Vision for the Future
Dr. Scholze also expressed enthusiasm about joining Rezon Bio during what he described as an exciting period in the company’s evolution.
He explained that he was attracted by several aspects of the organization, including its proven track record, scientific expertise, advanced manufacturing capabilities, and highly skilled workforce.
He also pointed to the company’s ambitious international growth strategy as an important factor in his decision.
Looking ahead, Dr. Scholze said he looks forward to working closely with both internal teams and clients to establish long-term strategic partnerships, expand Rezon Bio’s global presence, and help accelerate the development of innovative biologic therapies for patients around the world.
Delivering a Seamless Client Experience
One of Dr. Scholze’s primary objectives will be enhancing the overall customer experience throughout the development lifecycle.
As biologic drug development becomes increasingly complex, sponsors are placing greater emphasis on selecting CDMO partners capable of providing continuity across development stages while maintaining clear communication and consistent project management.
By aligning business development, proposal management, project execution, and customer engagement under a unified commercial strategy, Rezon Bio aims to create a smoother development journey for clients while reducing operational complexity.
This integrated approach is expected to strengthen long-term relationships and improve collaboration across multidisciplinary development programs.
Academic Foundation in Biochemistry
Dr. Scholze’s scientific background complements his extensive commercial experience.
He earned a Doctorate (Ph.D.) in Biochemistry from the University of Technology Graz in Austria, providing him with a strong understanding of molecular biology, protein science, and bioprocess development.
This scientific training enables him to engage effectively with research teams, manufacturing specialists, and biotechnology innovators while bridging the gap between technical development and commercial strategy.
Positioning for Continued International Expansion
As the global biologics market continues to experience strong growth, CDMOs are increasingly expected to provide integrated, flexible, and globally connected services that help accelerate therapeutic development while maintaining high standards of quality and regulatory compliance.
Through the appointment of Dr. Hubert Scholze as Chief Business Officer, Rezon Bio is reinforcing its commitment to becoming a leading international partner for biologics development and manufacturing. His combination of manufacturing expertise, commercial leadership, scientific knowledge, and extensive industry experience positions the company to expand its global footprint, strengthen strategic collaborations, and support clients developing both biosimilars and innovative biologic medicines from early development through commercial manufacturing.
With a strengthened leadership team and continued investment in its integrated CDMO platform, Rezon Bio aims to further enhance its ability to help biotechnology and pharmaceutical companies bring life-changing biologic therapies to patients worldwide.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
